Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.14 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:48 PM 05/20/15 All times are local (Market data is delayed by at least 15 minutes).

regeneus ltd (RGS) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/14 - A$0.40
52 Week Low
10/7/14 - A$0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REGENEUS LTD (RGS)

Related News

No related news articles were found.

regeneus ltd (RGS) Related Businessweek News

No Related Businessweek News Found

regeneus ltd (RGS) Details

Regeneus Ltd, a regenerative medicine company, develops and commercializes stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions in Australia. The company provides HiQCell, an autologous adipose derived stem cell therapy for human osteoarthritis and other musculoskeletal conditions. It also offers animal health products comprising CryoShot, an allogeneic cell-based product for use as an intra-articular injection for osteoarthritis, an adjunct to joint surgery, and an intra-lesional injection for tendinopathy in canine and equine markets; and Kvax, an autologous therapeutic cancer vaccine. In addition, the company is developing a stem cell secretions cream for inflammatory skins conditions, such as acne, rosacea, and psoriasis; and Progenza, an allogeneic cell therapy treatment for human osteoarthritis. Regeneus Ltd was founded in 2007 and is headquartered in Pymble, Australia.

Founded in 2007

regeneus ltd (RGS) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: A$440.5K
Chief Scientific Officer and Executive Direct...
Total Annual Compensation: A$339.5K
Compensation as of Fiscal Year 2014.

regeneus ltd (RGS) Key Developments

Regeneus Ltd Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:50 PM

Regeneus Ltd Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:50 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: John Dominic Martin, Chief Executive Officer, Director, Member of Audit & Risk Committee and Member of Remuneration & Nominations Committee.

Regeneus Ltd Appoints Glen Richards as an Independent Non-Executive Director, Effective April 2015

Regeneus Ltd. announced the appointment of Dr. Glen Richards as an independent non-executive director of the company with effect from April. Dr. Richards was the founding Managing Director of Greencross and over 20 years built it into Australia's veterinary healthcare group with over 115 veterinary practices and 195 vet specialty stores and led its merger with Petbarn. Dr. Richards continues as a non-executive director of Greencross.

Regeneus Ltd Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Regeneus Ltd. reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue of $1,140,958 against $782,625 a year ago. Loss before income tax was $5,737,288 against $6,364,777 a year ago. Loss for the period was $5,737,288 against $6,364,777 a year ago. Basic and diluted earnings per share from continuing operations was $0.03 against $0.04 a year ago. Net cash used in operating activities was $1,956,621 against $3,849,173 a year ago. Purchase of property, plant and equipment was $149,250 against $117,052 a year ago. Purchase of intangibles was $14,839 against $1,181 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGS:AU A$0.14 AUD 0.00

RGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Orthocell Ltd A$0.38 AUD +0.005
View Industry Companies

Industry Analysis


Industry Average

Valuation RGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.6x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENEUS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at